Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension

Jeffrey Hyams Connecticut Children’s Medical Center, Hartford, CT, USACorrespondence[email protected]

Thomas D. Walters The Hospital for Sick Children, Toronto, Canada

Wallace Crandall Nationwide Children’s Hospital, Columbus, OH, USA

Subra Kugathasan Emory University School of Medicine, Atlanta, GA, USA

Anne Griffiths The Hospital for Sick Children, Toronto, Canada

Marion Blank Centocor Research & Development, Inc., Malvern, PA, USA

Jewel Johanns Centocor Research & Development, Inc., Malvern, PA, USA

Yinghua Lang Centocor Research & Development, Inc., Malvern, PA, USA

James Markowitz Schneider Children’s Hospital, New Hyde Park, New York, USA

Stanley Cohen Children’s Center for Digestive Health Care, Atlanta, GA, USA

Harland S. Winter Massachusetts General Hospital for Children, Boston, MA, USA

Gigi Veereman-Wauters Queen Paola Children’s Hospital, Antwerp, Belgium

George Ferry Texas Children’s Hospital, Houston, TX, USA

Robert Baldassano Children’s Hospital of Philadelphia, Philadelphia, PA, USA and the REACH Study Group

References